Viscosupplementation, a minimally invasive medical procedure, has emerged as a significant treatment method for osteoarthritis, particularly in addressing the challenges associated with stiff joints, notably in the knees. At the core of this therapeutic approach is the injection of hyaluronic acid into the affected joints, aiming to alleviate stiffness, reduce friction between bones, and impede further degradation of bone tissues. The viscosupplementation procedure is distinctly categorized into three product cycles, each offering varying treatment regimens: the single-injection cycle, the three-injection cycle, and the five-injection cycle.
In the realm of osteoarthritis treatment, the single-injection cycle has garnered considerable attention for its safety profile and minimally invasive nature. This approach involves a one-time injection of hyaluronic acid into the knees, specifically designed to address knee osteoarthritis. The single-injection cycle has become increasingly popular due to its high patient compliance rate and the inherent advantage of requiring fewer hospital visits.
The Asia-Pacific (APAC) region has emerged as a key player in the global viscosupplementation market. This growth is attributed to a notable shift in consumer preferences, with individuals opting for less costly and minimally invasive procedures like viscosupplementation over traditional, more painful knee replacement surgeries. The demand for viscosupplementation in the APAC region is driven by the desire for optimum cost-effectiveness and a procedure that consumes less time compared to its alternatives.
Osteoarthritis, particularly affecting the knees, has become a prevalent health concern. The efficacy of viscosupplementation in managing symptoms and potentially slowing down the progression of knee osteoarthritis has led to its widespread adoption. The procedure's success lies not only in its clinical benefits but also in its ability to align with the preferences of patients seeking alternatives to more intrusive interventions.
The single-injection cycle, with its singular shot approach, aligns with the current trends in patient-centered care. The reduction in the number of hospital visits is a significant factor contributing to its popularity, making it a convenient choice for those seeking effective yet less disruptive treatment options.
As the global healthcare landscape continues to evolve, with an emphasis on patient-centric and minimally invasive interventions, the demand for viscosupplementation is expected to rise. The Asia-Pacific region, in particular, stands out as a growth frontier, reflecting the broader trend of shifting preferences toward less painful, cost-effective, and time-efficient medical procedures.
Viscosupplementation's role in osteoarthritis treatment, particularly in the knees, underscores the transformative potential of minimally invasive approaches in healthcare. The single-injection cycle, with its patient-friendly attributes, epitomizes the direction in which medical interventions are evolving. As global healthcare embraces more personalized and accessible solutions, viscosupplementation stands as a beacon of innovation, offering relief to those grappling with the challenges of knee osteoarthritis.
Report Attribute/Metric | Details |
---|---|
Segment Outlook | Product, Material Class,Application, and End Use Geographies Covered Americas, Europe, Asia-Pacific, Middle East & Africa Key Vendors Stryker (US), CoorsTek Inc (US), Zimmer Biomet Holdings Inc (US), Institut Straumann AG (Switzerland), Kyocera Corporation (Japan), Smith& Nephew plc (UK),3M (US), NobelBiocare Services AG(Switzerland), Medtronic plc (Ireland), DePuy Synthes (US). Key Market Opportunities Technological advancement in the medical implant market, Adoption of growth strategies by key players. Key Market Drivers Growing demand for next-generation orthopedic biomaterials, increasing older population leading to increase in patient population, rising prevalence of orthopedic diseases. |
Orthopedic Biomaterials Market Size was valued at USD 30.39 Billion in 2023. The Global Orthopedic Biomaterials industry is projected to grow from USD 33.33 Billion in 2024 to USD 64.22 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.56% during the forecast period (2024 - 2032). Orthopedic biomaterials are implanted in the human body as constituents. These devices are designed to perform certain biological functions by substituting or repairing different tissues such as bone, cartilage, or ligaments and tendons and even guiding bone repair when necessary.
The growth of the orthopedic biomaterials market is driven by factors such as the growing demand for next-generation orthopedic biomaterials and the increasing prevalence of orthopedic diseases. In addition, the increasing prevalence of chronic diseases creates a lucrative opportunity for the market. However, lack of reimbursement and an ambiguous regulatory framework is likely to restrain the market growth.
COVID-19 Analysis:
The pandemic is likely to have devastating effects on the global economy, more intense than the global financial crisis during 2008-2009. It is affecting the demand and supply chain, which will severely hurt global trade. The top players in the market are expected to continue to fulfill the current demand for orthopedic biomaterials, including reconstructive joint replacements and spinal implants. Furthermore, various governments across the world are encouraging the key players to improve the current manufacturing facilities. However, with the decline in elective surgical procedures, the orthopedic biomaterials market is expected to witness a slump in 2020.
Geriatric individuals are more susceptible to orthopedic diseases. Thus, the growing geriatric population is likely to increase the demand for orthopedic biomaterials. According to the Office for National Statistics, in 2017, ~18% and 2.4% of the total UK population was aged over 65 years and 85 years, respectively. With the high incidence of joint replacement procedures, over 1 million hip and total knee replacement procedures are performed each year in the US. This huge number of joint and knee replacements is increasing the demand for orthopedic biomaterial. Therefore, the growing elderly population is anticipated to boost the growth of the global orthopedic biomaterials market over the assessment period.Growing demand for next-generation orthopedic biomaterials
Limited reimbursement coverage options are present for these products. The reimbursement for orthopedic biomaterials is also declining in various countries, which has impeded market growth. This lack of reimbursements has put pressure on manufacturers to lower the prices for these materials. All these factors have restricted the growth of the market.
Nowadays, consumers are becoming more conscious and aware of the issues related to health. Thus, companies are focusing more on research & development to introduce better technology and treatment, which gives them an edge over their competitors. Companies are looking forward to introducing innovative technologies. Currently, several devices are present in the market for various medical conditions. Players focus on the development of technologically advanced products. For instance, in September 2019, Zimmer Biomet Holdings, Inc., a US-based healthcare solutions provider, announced FDA 510(k) clearance for the Persona Revision Knee System for revision knee replacement procedures. It offers components designed to match a patient's anatomy for a personalized fit.
The global orthopedic biomaterials market is growing steadily due to the rising incidence of orthopedic injury and growing demand for next-generation orthopedic biomaterial. So,with the rising use of orthopedic biomaterial, many players are showing keen interest in launching new products. The value chain analysis of the orthopedic biomaterials market comprises four major components: the software development process and designing, followed by R&D and designing, manufacturing, distribution, marketing,and sales with post-selling services.
Reconstructive joint replacement is a medical procedure that includes the replacement of the damaged joint. It includes minor repair to total joint replacement, and offers pain relief as well as permanent solutions to joint disorders. Reconstructive joint replacements include various types of implants, such as knee replacement implants, hip replacement implants, and others. According to the American Academy of Orthopedic Surgeons (AAOS), around 1.6 million hip and knee surgeries and 966,000 knee replacements were performed in the US in 2017.
The market growth of this segment is attributed to the increasing geriatric population and rising cases of orthopedic surgery. Moreover, there has been a strong focus on improving healthcare services globally, which further boosts the market's growth.
A spinal implant is a type of medical device used in the management of spine disorders. Spinal implants consist of polyetheretherketone (PEEK) and titanium alloys. Cobalt chromium alloys are used in disc replacements type of spinal implants. As per the North American Spine Society, around 1.4 million spinal procedures were performed each year in the US. The largest number of procedures were performed in cervical repair, with over 350,000 total procedures.
Dental implants are a type of surgical component that edges with the jaw's bone to support dental prostheses like crowns, dentures, and facial prostheses. Moreover, the modern dental implant is a biological process also known as osseointegration, in which titanium material is used to form a close bond to the bone. Dental implants have two types such as root-form dental implants and plate-form dental implants.
Trauma is a critical injury to the bones, joints, ligaments, muscles, and soft tissue caused by accident and fall. As per the World Health Organization, prevalence of trauma orthopedic injury is around 63.6%.
Orthobiologics are biological substances used to provide relief in musculoskeletal injuries.Orthobiologics are various types such as viscosupplementation, demineralized bone matrix, synthetic bone substitutes, bone morphogenetic proteins, and allograft.
This segment includes orthopedic biomaterials such as bio-resorbable tissue fixation, and osteosynthesis among others.
With the magnum PI's polyetheretherketone (PEEK) implant material systems, surgeons who choose not to use metal anchors may incorporate alternatives. The system can be seen in several shoulder-related surgical operations and Achilles tendon replacements, among many other indications. Together with cortical bone lock, knotless fixation, and a simple technique, an implant makes the procedure quick, effective, and secure. The implant is put in an easy-to-use implanted handle.
The rising geriatric population, rapid adoption of new technologies, rising prevalence of osteoporosis, and increasing injuries are the main factors for the growth of the orthopedic fracture fixation segment. Changes in the lifestyle, such as lack of exercise, early burnout, and increased obesity amongst people are resulting in the weakening of bone fractures, which drive the growth of theorthopedicbiomaterials market.
Sportspersons recovering from athletic injuries isa significant factor supporting the market growth of soft tissue fixation. The incidence of sports accidents, which is projected to fuel the market growth, will also increase with a growing number of children and teenagers taking part in sports activities.
Orthopedic implants are used to repair or sustain a broken or deformed bone or joint. These implants are designed to cure posture issues, regain natural skeletal functions, and remove deformities. An orthopedic implant is to replace older prosthetics. The demand for orthopedic implant products has increased due to a rise in the geriatric population, raising the risk of osteoporosis, osteoarthritis, and other musculoskeletal disorders.
Viscosupplementation is a minimally invasive technique in which an injection of hyaluronic acid (an active compound in synovial fluid) is commonly used. The bulk of the orthopedic operations are performed in the leg. There are 1 to 3 injection procedures with 3-injection treatments showing better pain relief than a 1-injection regimen.
There has been a significant increase in the number of hospital admissions and patient visits for orthopedic surgeries in the majority of the countries. In 2017, the number of orthopedic surgery procedures performed globally totaled around 22.3 million. The hospitals & clinics segment dominated the global orthopedicbiomaterials market in 2019 in terms of revenue.
Ambulatory Surgery Centersor ASCs, are modern healthcare facilities where surgeries do not require hospital admission and provide same-day surgical care, including diagnostic and preventive procedures. The orthopedic biomaterial provided by ASCs is anticipated to increase the number of patients opting for orthopedic injury during the forecast period.
The others segment includes research& academics, nursing homes, etc. The growth of the segment is attributed to the growing use of orthopedic biomaterial in various orthopedic diseases.
Regional Analysis
Americas:
The Americas dominated the orthopedicbiomaterials market in 2019 and is likely to continue during the assessment period as well. This can be attributed to the high prevalence of orthopedic diseases, product launches, and technological advancement in this region. The high demand for orthopedic biomaterials and the adequate availability of skilled professionals in the region are expected to fuel the regional market growth. The growing elderly population is also resulting in the growth of the orthopedicbiomaterials market in the Americas. As per the Administration for Community Living, in the Americas, over the last ten years, the population aged 65 and over grew from 37.2 million in 2006 to 49.2 million in 2016.
Europe:
Europe held the second-largest position in the orthopedic biomaterials market in 2019 and is anticipated to witness significant growth over the forecast period due to a higher number of patients and the availability of products in the region. In 2017, Switzerland, Finland, Luxembourg, Germany, Austria, and Belgium were among the countries with the highest number of hip and knee replacements in the region. The OECD averages are 182 per 100,000 population for hip replacements and 135 per 100,000 for knee replacements. On average, hip replacement rates increased by 30% between 2007 and 2017, and knee replacement rates increased by 40% in the same period. This increase in patients undergoing knee and replacement is anticipated to boost the regional market's growth.
Asia-Pacific:
The Asia-Pacific is anticipated to register the highest growth rate duringthe forecast period. According to the United Nations, across Asia, the number of people aged 65 and above is expected to grow dramatically over the next 50 years. For the region, the population in this age group will increase by 31.4%, from 207 million in 2000 to 857 million in 2050. A large number of adults residing in the region are expected to suffer from various orthopedic disorders. This is expected to drive the growth of the regional orthopedicbiomaterials market during the study period.
Middle East & Africa:
The orthopedic biomaterials market in the Middle East & Africa has been growing steadily in recent years. The key factors propelling the growth of the regional market are the increasing the prevalence of orthopedics disorders and funding by private players and government bodies.
The global orthopedic biomaterials market is characterized by the presence of many global, regional, and local vendors catering to the demand created by a large patient pool in need of diagnostic and surgical services. The availability of innovative products is increasing the lucrativeness of the global orthopedic biomaterials market. The key players have adopted the strategy of signing contracts and agreements to expand their global presence and optimize operational costs.
The market is highly competitive, with players competing and partnering to gain a substantial market share. The global orthopedic biomaterials market is moderately consolidated with rising competition, product launches, rising collaborative partnerships, and other strategic decisions to achieve operational efficiency. The vendors compete based on cost, quality, timely availability, and reliability of products offered. It is decisive for the players operating in the orthopedic biomaterials market to provide cost-efficient products to survive and succeed in an increasingly competitive and growing market environment.
List of Key Companies Covered in this Report:
Report Overview:
The report contains:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)